← Leaderboards
Scott A Rollins
Selexys Pharmaceuticals Corporation
$10,675,065
Attributed
$10,675,065
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2009–16$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$9,569,670 · 2
FDA$1,105,395 · 1
By mechanism
R44$9,569,670 · 2
R01$1,105,395 · 1
Top collaborators
No co-investigators on record.
Most similar at Selexys Pharmaceuticals Corporation
Same institution · by research overlap
- Ziad Samir Kawar$304,843
Others in their field
Top investigators on “Pharmacologic Substance”
- David Heimbrook · Leidos Biomedical Research, Inc.$127,683,054
- Myron S Cohen · Family Health International$104,232,876
- Wafaa M. El-Sadr · Columbia University Health Sciences$104,068,526
- Garret A Fitzgerald · University Of Pennsylvania$73,814,804
- James Dennis Neaton · Northwestern University$65,107,995
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$53,206,876
Research focus
Pharmacologic SubstanceSafetyMacaca FascicularisPharmaceutical PreparationsPreventionProgramsInflammatoryDesignMediatingPersonsPreclinical StudyPreventGrantHumanized AntibodyAffectDoseAntibodiesContractsClinical ResearchEffective TherapyMedicalClinical TrialsBaseImmunogenicity
Grant awards (12)
Phase 2 Study of SelG1 for the Treatment of Sickle Cell Disease$364,000
R01 · FY2016 · FD · contact PI
Phase 2 Study of SelG1 for the Treatment of Sickle Cell Disease$400,000
R01 · FY2015 · FD · contact PI
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea$1,037,638
R44 · FY2014 · HL · contact PI
Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease$966,321
R44 · FY2014 · DK · contact PI
Phase 2 Study of SelG1 for the Treatment of Sickle Cell Disease$341,395
R01 · FY2014 · FD · contact PI
Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease$310,350
R44 · FY2014 · DK · contact PI
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea$1,037,638
R44 · FY2013 · HL · contact PI
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea$1,037,638
R44 · FY2012 · HL · contact PI
Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease$1,276,671
R44 · FY2011 · DK · contact PI
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea$2,091,208
R44 · FY2010 · HL · contact PI
Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease$560,627
R44 · FY2010 · DK · contact PI
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea$1,251,579
R44 · FY2009 · HL · contact PI